Gene therapy company Genprex Inc (NASDAQ: GNPX) announced on Monday that its research collaborators from Meharry Medical College will present promising preclinical data on Reqorsa Gene Therapy at the 39th Annual Society for Immunotherapy of Cancer (SITC) meeting from 6-10 November 2024 in Houston, Texas.
The poster, titled 'TUSC2 Modulates Cancer Immune Responses', will highlight Reqorsa's ability to influence immune responses against cancer cells.
Reqorsa, Genprex's lead drug candidate, utilises the TUSC2 tumor suppressor gene delivered through the company's Oncoprex Delivery System, a lipid nanoparticle platform designed to target and deliver TUSC2 to cancer cells while sparing normal tissue. Preclinical studies demonstrated significantly higher TUSC2 uptake in cancer cells compared to normal cells.
Genprex is focused on developing therapies for cancer and diabetes. Reqorsa is currently being tested in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with both programs receiving FDA Fast Track Designation. The SCLC program also holds an FDA Orphan Drug Designation.
Faron Pharmaceuticals files patent for soluble Clever-1 in autoimmune disease treatment
Robles BioCeutics collaborates with BioCentrium
Nammi Therapeutics doses first patient in QXL138AM first in human Phase one trial (NCT06582017)
HUYABIO reveals data from phase two study assessing HBI-8000 in combination with nivolumab
Johnson & Johnson seeks approval for DARZALEX FASPRO in smoldering multiple myeloma
Bruker unveils EpicIF technology, doubling throughput in CellScape platform
Harbour BioMed submits IND application for HBM9378/SKB378 in COPD treatment
AstraZeneca's Tezspire achieves positive results in nasal polyps trial
OncoResponse announces OR502 Phase one trial results
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Royalty Pharma acquires RYTELO royalty interest from Geron
Minghui Pharmaceutical announces initial MHB039A Phase I clinical trial results
REGENXBIO reports reduced net loss for nine months to September 2024